258 related articles for article (PubMed ID: 26300875)
1. The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.
Evans JC; Mizrahi V
Front Microbiol; 2015; 6():812. PubMed ID: 26300875
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput target-based screening approach for the identification and assessment of
Smiejkowska N; Oorts L; Van Calster K; De Vooght L; Geens R; Mattelaer H-P; Augustyns K; Strelkov SV; Lamprecht D; Temmerman K; Sterckx YG-J; Cappoen D; Cos P
Microbiol Spectr; 2024 Mar; 12(3):e0372323. PubMed ID: 38315026
[TBL] [Abstract][Full Text] [Related]
5. Current possibilities and unresolved issues of drug target validation in Mycobacterium tuberculosis.
Sharma U
Expert Opin Drug Discov; 2011 Nov; 6(11):1171-86. PubMed ID: 22646985
[TBL] [Abstract][Full Text] [Related]
6. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
Sharma A; Jain K; Flora SJS
Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
[TBL] [Abstract][Full Text] [Related]
7. The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery.
Yuan T; Werman JM; Sampson NS
RSC Chem Biol; 2021 Apr; 2(2):423-440. PubMed ID: 33928253
[TBL] [Abstract][Full Text] [Related]
8. Identification and evaluation of a new nucleic acid amplification test target for specific detection of Mycobacterium tuberculosis.
Qin L; Zheng R; Fan C; Cai J; Liu Z; Wang J; Lu J; Jin R; Yang H; Cui Z; Feng Y; Hu Z
Clin Chem Lab Med; 2010 Oct; 48(10):1501-5. PubMed ID: 20658950
[TBL] [Abstract][Full Text] [Related]
9. Computational insights into promoter architecture of toxin-antitoxin systems of Mycobacterium tuberculosis.
Thakur Z; Saini V; Arya P; Kumar A; Mehta PK
Gene; 2018 Jan; 641():161-171. PubMed ID: 29066303
[TBL] [Abstract][Full Text] [Related]
10. Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro Validation.
Mehra R; Rani C; Mahajan P; Vishwakarma RA; Khan IA; Nargotra A
ACS Comb Sci; 2016 Feb; 18(2):100-16. PubMed ID: 26812086
[TBL] [Abstract][Full Text] [Related]
11. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
[TBL] [Abstract][Full Text] [Related]
12. Hit Generation in TB Drug Discovery: From Genome to Granuloma.
Yuan T; Sampson NS
Chem Rev; 2018 Feb; 118(4):1887-1916. PubMed ID: 29384369
[TBL] [Abstract][Full Text] [Related]
13. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
14. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
Wellington S; Hung DT
ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
[TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
16. Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes.
Johnson EO; LaVerriere E; Office E; Stanley M; Meyer E; Kawate T; Gomez JE; Audette RE; Bandyopadhyay N; Betancourt N; Delano K; Da Silva I; Davis J; Gallo C; Gardner M; Golas AJ; Guinn KM; Kennedy S; Korn R; McConnell JA; Moss CE; Murphy KC; Nietupski RM; Papavinasasundaram KG; Pinkham JT; Pino PA; Proulx MK; Ruecker N; Song N; Thompson M; Trujillo C; Wakabayashi S; Wallach JB; Watson C; Ioerger TR; Lander ES; Hubbard BK; Serrano-Wu MH; Ehrt S; Fitzgerald M; Rubin EJ; Sassetti CM; Schnappinger D; Hung DT
Nature; 2019 Jul; 571(7763):72-78. PubMed ID: 31217586
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
18. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
Chae H; Shin SJ
J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
20. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
Cooper CB
J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
